Aspichi

Cover Block

PUBLIC

Company Details
Name	Aspichi
Tagline	AI-powered VR/MR therapy for mental health
Headquarters	Kyiv, Ukraine
Founded	2022
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	AI / Machine Learning
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$1,200,000)

Links

PUBLIC

• Website: https://aspichi.com
• LinkedIn: https://www.linkedin.com/company/aspichi

Executive Summary

PUBLIC

Aspichi is a Ukrainian healthtech startup that uses AI-driven virtual and mixed reality to scale the delivery of mental health therapy, a bet that deserves attention for its attempt to address systemic clinician shortages through immersive technology [AIN, July 2024]. Founded in Kyiv in 2022 by Viktor Samoilenko and Maksym Goncharuk, the company has secured approximately $1.2 million in seed capital, primarily from the SMRK VC Fund, to develop and launch its flagship Luminify platform [AIN, March 2023] [Wellfound]. The product differentiates by combining 360-degree spatial video with VR headsets and an AI layer to automate and standardize treatment for conditions like anxiety and PTSD, aiming to increase patient capacity for clinics [AIN, July 2024]. The founding team's public profiles show operational and technical leadership, though their specific backgrounds in clinical healthcare or enterprise sales are not detailed in available sources [LinkedIn]. The business model is B2B, targeting healthcare organizations, with an early U.S. beachhead established through a partnership with Rocky Mountain Care [Odessa Journal]. Over the next 12-18 months, the key watchpoints will be the validation of clinical outcomes from that partnership, the conversion of initial deployments into a repeatable sales motion, and the company's ability to raise a substantive Series A round to fund expansion beyond its current seed-stage runway.

Data Accuracy: YELLOW -- Core product and founding details are confirmed by multiple sources; key traction and financial metrics are sourced from a single, unverified platform.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	Eastern Europe
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding	Seed (total disclosed ~$1,200,000)

Company Overview

PUBLIC

Aspichi was founded in 2022 in Kyiv, Ukraine, by Viktor Samoilenko and Maksym Goncharuk [Crunchbase]. The company operates as a B2B software provider, with its primary product, Luminify, designed to deliver AI-driven virtual and mixed reality therapy for conditions like anxiety, depression, and PTSD [AIN, Jul 2024]. Its operational base remains in Ukraine, but the firm has pursued a clear expansion strategy into the United States, a move formalized by a 2024 partnership with the American healthcare organization Rocky Mountain Care [Odessa Journal].

Key corporate milestones follow a pattern of incremental capital raises to fund this expansion. The company secured its first known external funding in April 2023, a $500,000 seed round led by the Ukrainian SMRK VC Fund [AIN, Mar 2023]. This was followed by two smaller seed rounds in September 2024 ($600,000) and July 2025 ($100,000), along with a grant in September 2025, bringing total disclosed funding to approximately $1.2 million [Wellfound] [CB Insights Financials]. The partnership with Rocky Mountain Care, announced in mid-2024, stands as the most significant commercial milestone to date, marking the company's entry into the U.S. clinical market [AIN, Jul 2024].

Data Accuracy: YELLOW -- Core facts (founding year, founders, initial funding) are confirmed by multiple sources. Later funding rounds and the key partnership are reported by single, non-major publishers.

Product and Technology

MIXED

Aspichi's core product is Luminify, a software platform that uses virtual and mixed reality to deliver therapeutic interventions for mental health conditions. The system combines 360-degree spatial video streaming with VR headsets and proprietary AI to treat anxiety, depression, and PTSD [AIN, July 2024]. The company's public messaging frames this as a capacity expansion tool, designed to help clinics serve more patients by automating and standardizing aspects of therapy through immersive, repeatable experiences [AIN, July 2024].

From a technical perspective, the product is delivered as a B2B service to healthcare organizations. The AI component is described as driving the therapy, though specific model architectures or training datasets are not detailed in public sources. The partnership with Rocky Mountain Care, an American healthcare organization, serves as the primary public deployment case, indicating the platform is operational in a clinical setting [Odessa Journal]. Reported metrics from this deployment include positive clinical results, though quantitative outcomes data is not published [Odessa Journal].

• Deployment model. The company appears to manage the software and content, while clinics provide the hardware (VR headsets) and clinical oversight. This suggests a SaaS-like model, though pricing is not disclosed.
• Content library. The use of 360-degree video implies a curated library of therapeutic environments or scenarios, a common approach in digital therapeutics for exposure therapy or relaxation training.
• Tech stack (inferred). The requirements for streaming high-fidelity spatial video and running real-time AI analytics point to a cloud-based backend, with applications likely built for commercial VR hardware like Meta Quest.

Data Accuracy: YELLOW -- Product description is consistent across multiple sources, but technical specifics and performance data are limited to company and partner announcements.

Market Research

PUBLIC

The addressable market for digital mental health interventions is expanding, driven by a persistent gap between clinical need and provider capacity. For a company like Aspichi, the core proposition is not merely creating a new therapeutic tool, but scaling the delivery of existing evidence-based treatments through technology.

Quantifying the specific market for AI-driven VR therapy is challenging, as it sits at the intersection of several larger, adjacent sectors. The global digital mental health market was valued at over $20 billion in 2023, with projections for high single-digit annual growth through the decade [Grand View Research, 2024]. Within this, the virtual reality in healthcare segment is a smaller, faster-growing niche. One analogous market sizing for VR in behavioral health, which includes exposure therapy and stress management, estimated a market size of $1.2 billion in 2024, growing to over $4 billion by 2030 [Precedence Research, 2024]. These figures provide a directional sense of the segment's potential, though they are not specific to Aspichi's exact product mix.

Demand is propelled by several converging tailwinds. The global shortage of mental health professionals is well-documented, creating pressure on healthcare systems to find capacity-multiplying solutions. Payer receptivity is increasing, with some U.S. health plans now covering FDA-authorized digital therapeutics for conditions like substance use disorder and insomnia, setting a precedent for reimbursement of software-based interventions [American Journal of Managed Care, 2023]. Furthermore, the pandemic accelerated both patient and provider comfort with telehealth, lowering the barrier to adopting novel digital care modalities.

The competitive landscape includes not just direct VR therapy platforms, but a range of substitutes and adjacencies. These include traditional in-person therapy, broader telehealth platforms offering video sessions, and a growing array of mobile app-based cognitive behavioral therapy (CBT) programs. The regulatory environment is a critical force. In the U.S., the FDA's Digital Health Center of Excellence is shaping a clearer pathway for Software as a Medical Device (SaMD), though Aspichi's current offering appears positioned as a clinical decision support tool rather than a regulated device, based on available descriptions [AIN, July 2024]. Macro forces, including rising mental health awareness and employer-driven wellness programs, are creating additional demand channels beyond traditional clinical settings.

Digital Mental Health (Global, 2023) | 20 | $B
VR in Behavioral Health (Global, 2024) | 1.2 | $B
VR in Behavioral Health (Projected, 2030) | 4 | $B

The chart illustrates the nesting of Aspichi's target niche within larger, established markets. The company's serviceable obtainable market (SOM) is initially defined by its specific clinic partnerships, like Rocky Mountain Care [Odessa Journal], but the cited growth projections for the VR behavioral health segment suggest a credible expansion runway if clinical efficacy and unit economics are proven.

Data Accuracy: YELLOW -- Market sizing figures are from third-party analyst reports for analogous sectors, not specific to the company's product. Tailwind and regulatory observations are supported by general industry reporting.

Competitive Landscape

MIXED

Aspichi's wedge into the mental health market is defined by its focus on immersive, AI-driven therapy delivered through VR/MR, a space where competition is fragmented between clinical software specialists and broader wellness platforms.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
Aspichi	AI-powered VR/MR therapy for anxiety, depression, PTSD in clinical settings.	Seed (~$1.2M disclosed). Kyiv-based, US expansion via partnerships.	Combines 360-degree spatial video streaming with AI for clinician-led, scalable treatment.	[AIN, Jul 2024]
XRHealth	VR/AR telehealth platform for physical and mental health rehabilitation.	Later stage; raised $10M Series A in 2021. US & Israel-based.	FDA-cleared platform with a broader focus on both physical therapy and mental health, established US payer relationships.	[Crunchbase]
Psious	VR platform for mental health professionals treating anxiety disorders and phobias.	Venture-backed; raised ~$8M. Barcelona-based.	Strong focus on exposure therapy with a large library of pre-built virtual environments, used in over 1,000 clinics globally.	[Crunchbase]
BehaVR	Digital therapeutics using VR for chronic disease and mental health management.	Acquired by OxfordVR in 2022. US-based.	Originally focused on prescription digital therapeutics (PDTs) with clinical validation for specific conditions like substance use disorder.	[Crunchbase]

The competitive map breaks into three tiers. At the top are integrated clinical platforms like XRHealth, which offer a full-stack telehealth solution with regulatory clearances and established reimbursement pathways [Crunchbase]. These are the incumbents Aspichi must displace or partner with. The second tier consists of pure-play mental health VR specialists such as Psious, which compete directly on therapeutic content libraries for anxiety disorders [Crunchbase]. Adjacent substitutes include a wide range of digital mental health apps (e.g., Calm, Headspace) and teletherapy services, which compete for patient attention and healthcare budgets but lack the immersive, clinician-supervised modality Aspichi offers.

Aspichi's current edge appears to be its specific technological integration and capital-efficient, partnership-led distribution. The company's Luminify platform is described as combining 360-degree video with AI, suggesting a focus on creating realistic, adaptive therapeutic environments rather than static VR experiences [AIN, Jul 2024]. This technical differentiation, however, is perishable without continuous investment in content development and clinical validation. A more durable, if nascent, advantage could be its early foothold in specific clinical partnerships, such as the deployment with Rocky Mountain Care in the United States [Odessa Journal]. This provides a real-world testing ground and a potential blueprint for a capital-light, asset-light expansion model that avoids the heavy lift of direct sales to large hospital systems.

The company's most significant exposure lies in its limited scale and unproven commercial engine relative to funded competitors. XRHealth's FDA clearances and existing payer contracts create a high regulatory and commercial moat that a seed-stage company cannot quickly replicate [Crunchbase]. Psious's extensive library of therapeutic environments and its multi-year head start in building a global clinician network represent another form of scaling barrier. Furthermore, Aspichi's reliance on third-party VR hardware (like Meta Quest) means it does not control a key part of the user experience or cost structure, leaving it vulnerable to platform policy changes or competition from hardware makers developing their own therapeutic software.

Over the next 18 months, the most plausible competitive scenario hinges on the validation and replication of its partnership model. If Aspichi can demonstrate improved patient outcomes and attractive unit economics through its Rocky Mountain Care deployment and sign two or three similar mid-sized clinic chains, it could carve out a sustainable niche as a specialized provider for anxiety and PTSD treatment. In this scenario, a winner like Psious might see its market share pressured in specific clinical segments where immersive, AI-adapted content proves superior to static exposure therapy. Conversely, if Aspichi fails to move beyond pilot deployments and its technology is matched by a better-funded incumbent, it becomes a likely acquisition target or risks fading into obscurity. The loser in that case would be Aspichi itself, as the capital required to build a full-stack clinical platform and sales force likely exceeds what its current investor base can provide.

Data Accuracy: YELLOW -- Competitor profiles and funding stages are drawn from Crunchbase, which provides consistent but unverified third-party data. Aspichi's own positioning is confirmed by a single trade publication [AIN, Jul 2024]. The partnership claim is sourced from a regional outlet [Odessa Journal] without a clear date.

Opportunity

PUBLIC

If Aspichi's technology proves effective and scalable, the opportunity is to become a primary capacity multiplier for mental health clinics, capturing a share of a global market where demand for therapy vastly outpaces the supply of clinicians.

The headline opportunity for Aspichi is to establish its Luminify platform as a category-defining, AI-driven standard for immersive therapy within outpatient clinics and rehabilitation centers. This outcome is reachable not because of speculative technology, but because the company's wedge is a clear operational problem: clinics need to serve more patients with limited clinical hours. Aspichi's approach, using standardized, AI-guided VR sessions, directly addresses this capacity constraint. The early partnership with Rocky Mountain Care, an American healthcare organization, provides a concrete, cited beachhead for this model [Odessa Journal]. While the scale of that deployment is not public, the existence of a U.S. partnership validates the core commercial hypothesis that healthcare providers will adopt third-party VR therapy tools.

Growth from a single partnership to meaningful scale requires specific, plausible pathways. The following scenarios outline how Aspichi could achieve breakout traction.

Scenario	What happens	Catalyst	Why it's plausible
Clinic Network Rollout	Rocky Mountain Care deploys Luminify across its full network of facilities, providing a multi-site revenue case study.	Successful pilot results lead to a broader enterprise contract.	The initial partnership is confirmed [Odessa Journal]; healthcare organizations often pilot in one location before scaling proven solutions.
Payor Reimbursement	A major U.S. health insurer agrees to reimburse for Luminify sessions, unlocking a vast patient pool.	Publication of positive clinical outcomes data from an early partner.	Digital therapeutics for mental health are gaining reimbursement pathways; a proven partnership provides a real-world evidence base.
White-Label Platform	Aspichi licenses its technology stack to larger digital health or hospital system software vendors.	A strategic partnership with a health IT company seeking VR capabilities.	The company's B2B focus and AI/VR stack are inherently licensable; this is a common scaling path for healthtech infrastructure.

Compounding success in this model would look like a classic data and distribution flywheel. Each new clinic deployment generates more patient interaction data, which Aspichi's AI uses to refine and personalize therapy protocols, theoretically improving outcomes. Better outcomes, in turn, strengthen the case for wider adoption within a health system and for reimbursement from payors. While there is no public evidence yet of this flywheel in motion, the company's product premise is built on it: the AI component "drives" the therapy [Crunchbase], implying a closed-loop system where usage improves the product. Early traction with 15 rehabilitation centers, as reported by one source, suggests the beginning of a multi-site distribution footprint [Incredible Tech].

The size of the win, should a major scenario play out, can be framed by looking at a comparable. XRHealth, a named competitor, provides a reference point. While XRHealth's valuation is not public, it has raised significantly more capital (over $70 million according to Crunchbase) and serves as an indicator of the venture-scale outcomes possible in the therapeutic VR space. If Aspichi successfully executes the Clinic Network Rollout scenario and captures a material portion of the U.S. outpatient mental health market, it could plausibly reach a valuation in the high tens or low hundreds of millions of dollars, following the trajectory of similar digital health platforms. This is a scenario-based outcome, not a forecast.

Data Accuracy: YELLOW -- Growth scenarios are extrapolated from a single confirmed partnership; the reported clinic count is from one unverified source.

Sources

PUBLIC

1. [AIN, March 2023] Ukrainian VR startup Aspichi secures $500k from the SMRK fund | https://en.ain.ua/2023/03/16/aspichi-secures-500k-from-smrk/

2. [AIN, July 2024] Ukrainian VR startup Aspichi launches in USA | https://en.ain.ua/2024/07/16/ukrainian-aspichi-launches-in-usa/

3. [Crunchbase] Aspichi - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/aspichi

4. [Wellfound] Aspichi | Wellfound | https://angel.co/

5. [CB Insights Financials] Luminify Stock Price, Funding, Valuation, Revenue & Financial Statements | https://www.cbinsights.com/company/aspichi/financials

6. [Odessa Journal] Aspichi: Ukrainian VR startup conquers the USA together with Rocky Mountain Care | https://elbuz.com/en/ukrainskij-startap-aspichi-vijshov-na-rinok-ssha-zapartnerivshis-z-rocky-mountai

7. [LinkedIn] Viktor Samoilenko - General Manager - H.Essers | LinkedIn | https://www.linkedin.com/in/viktor-samoilenko-2596366a/

8. [LinkedIn] Maksym Goncharuk - Chief Technology Officer - Aspichi | https://ua.linkedin.com/in/maksym-goncharuk-4b84883

9. [Incredible Tech] Aspichi | HEALTHTECH - INCREDIBLE TECH | https://incredibletech.org/healthtech/aspichi

10. [Grand View Research, 2024] Digital Mental Health Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/digital-mental-health-market

11. [Precedence Research, 2024] Virtual Reality in Behavioral Health Market Size, Growth, Report 2024-2032 | https://www.precedenceresearch.com/virtual-reality-in-behavioral-health-market

12. [American Journal of Managed Care, 2023] The Evolving Landscape of Digital Therapeutics and Payer Coverage | https://www.ajmc.com/view/the-evolving-landscape-of-digital-therapeutics-and-payer-coverage